|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Asymptomatic primary cytomegalovirus infection:virologic and immunologic features显示文摘 | Zanghellini F Boppana SB Emery VC | | 0，，03： | 1 |
| 2 | Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks 显示文摘 | Cohen SB Emery P Greenwald MW | 2006 | Arthritis Rheum2006，54，： | 1 |
| 3 | Increased activity of Diaphanous homolog 3 (DIAPH3)/diaphanous causes hearing defects in humans with auditory neuropathy and in Drosophila显示文摘 | Schoen C J Emery SB Thorne MC | 2010 | Proc Natl Acad Sci U S A2010，107，13： | 1 |
| 4 | Increased activity of Diaphanous homolog 3 (DIAPH3)/diaphanous causes hearing defects in humans with auditory neuropathy and in Drosophila显示文摘 | Schoen CJ Emery SB Thorne MC | 2010 | Proc Natl Acad Sci USA2010，107，13： | 1 |
| 5 | Increased activity of diaphanous homolog 3 (DIAPH3)/diaphanous causes hearing defects in humans with auditory neuropathy and in Drosophila 显示文摘 | Schoen CJ Emery SB Thorne MC | 2010 | Proc Natl Acad Sci USA2010，107，13： | 1 |
| 6 | Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a muhicenter, randomized, double-blind, place- bo-controlled, phase Ⅲ trial evaluating primary efficacy and safety at twenty-four weeks显示文摘 | Cohen SB Emery P Greenwald MW | 2006 | Arthritis Rheum2006，54，9： | 1 |
| 7 | Rituximab for rheu- matoid arthritis refractory to anti-tumor necrosis factor therapy: Re- suits of a multieenter, randomized, double-blind, placebo-con- trolled, phase m trial evaluating primary efficacy and safety at twenty-four weeks 显示文摘 | Cohen SB Emery P Greenwald MW | 2006 | Arthritis Rheum2006，54，9： | 1 |
| 8 | Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks 显示文摘 | Cohen SB Emery P Greenwald MW | 2006 | Arthritis Rheum2006，54，9： | 1 |
| 9 | Rituximab for rheuma- toid arthritis refractory to anti-tumor necrosis factor therapy : Results of a muhicentcr, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks显示文摘 | Cohen SB Emery P Greenwald MW | 2006 | Arthritis Rheum2006，54，9： | 1 |
| 10 | Increased activity of Diaphanous homolog 3 (DIAPH3)/diaphanous causes hearing defects in humans with auditory neuropathy and in Drosophila 显示文摘 | Schoen CJ Emery SB Thorne MC | 2010 | Proc Natl Acad Sci USA2010，107，13： | 1 |
| 11 | Asymptomatic primary cytomegalovirms infection:virologic and immunologic features显示文摘 | Zanghellini F Boppana SB Emery VC | | 0，，03： | 1 |
| 12 | Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy:Results of a rnulticenter,randomized,double -blind, placebo-controlled,phase Ⅲ trial evaluating primary efficacy and safety at twenty-four weeks显示文摘 | Cohen SB Emery P Greenwald MW | 2006 | Arthritis Rheum2006，54，9： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员